Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

TS03 Inc Trust Units TSTIF



GREY:TSTIF - Post by User

Post by echo2on Apr 29, 2016 1:17pm
196 Views
Post# 24826198

Q&A at the AGM-

Q&A at the AGM-Hope we will get some significant colour on the following at the AGM:

- status of R&D on the new OR suite '80L' (and, no, it will not compete with the VP4; it will be a new, smaller complimentary product in a new  'space' and will not compete with the larger robust VP4 as a replacement for Sterrad, Steris units)

- FDA extended claims approval progress (in light of recent FDA process to establish new claims a case by case basis; especially, regarding FDA consideration of the VP4 as a solution for ongoing Olympus Q180V duodenoscope contamination problems)

- plans for US listing (NASDAQ listing should be a given this year)

- hard numbers for orders and sales in Quarter 1 (market seems to have low and conservative expectations, here; solid numbers should allow for considerable analyst upgrades)

- strategic installs 

- new investor interest (especially in the US, in light of all of the recent road shows and health care conference and investor group presentations)

- plans for production capacity increases (in a new US facility to meet anticipated demand)

- plans and progress for the Myrtle Beach distribution facility (especially with some senior management now and in the future listing MB as their primary location)

- EU roll-out (has Getinge shown the VP4 at any recent sterilization or health care meetings?)(I am still not sure why TSO3's presentations list EU approval as a done deal, yet we have had no press releases specific to highlighting this very important fact....)

- patents pending update

The market has been disappointed by a lack of clarity with the past few Q&A's, and the absence of a share price run up in anticipation of positive news out of the AGM reflects this lack of enthousiasm, IMHO. TOS retains a desperately cheap valuation.

I do hope all of the above questions will be raised by those of you who are able to attend, or, perhaps, management will be proactive and address these things in their opening remarks. (I might have to cancel a surgery day and attend myself on short notice, should it appear others won't be able to ask these things. :) I agree, the Musee de Beaux Arts is a beautiful location for a meeting. Will be a delight. Hope they have some upbeat music to create a positive mood from the start! :)  ) WKH
<< Previous
Bullboard Posts
Next >>